Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer

Journal of Clinical Oncology

Volumn 14, Issue 7, 1996, Pages 2101-2112

  Kemp, George ^a   Rose, Peter ^a   Lurain, John ^a   Berman, Michael ^a   Manetta, Alberto ^a   Roullet, Bernard ^a   Homesley, Howard ^a   Belpomme, Dominique ^a   Glick, John ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; CISPLATIN; CYCLOPHOSPHAMIDE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SCREENING; FEMALE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; OVARY CANCER; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; VOMITING;

EID: 0029902007     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.7.2101     Document Type: Article

References (83)

1. Davidson DE, Grenan MM, Sweeney TR: Biological characteristics of some improved radioprotectors, in Brady LW (ed): Radiation Sensitizers. New York, NY, Masson, 1980; pp 309-320
2. Wasserman TH, Phillips TL, Ross G, et al: Differential protection against cytotoxic chemotherapeutic effects on bone marrow CPUs by WR-2721. Cancer Clin Trials 4:3-6, 1981
3. Valeriote F, Tolen S: Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721. Cancer Res 42:4330-4331, 1982
4. Millar JL, McElwain TJ, Clutterbuck RD, et al: The modification of melphalan toxicity in tumor bearing mice by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR-2721). Am J Clin Oncol 5:321-328, 1982
5. Yuhas JM, Spellman JM, Culo F: The role of WR-2721 in radiotherapy and/or chemotherapy. Cancer Clin Trials 3:211-216, 1980
6. Shpall EJ, Stemmer SM, Hami L, et al: Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood 83:3132-3137, 1994
7. Douay L, Hu C, Giarratana MC, et al: WR 2721 (ethiofos) protects normal progenitor/stem cells from cyclophosphamide derivatives toxicity, with preservation of their anti-leukemic effects: Application to in vitro marrow purging, in Guigon M (ed): The Negative Regulation of Hematopoiesis (ed 229). Paris, France, Colloque INSERM/John Libbey Eurotext, 1993, pp 469-476
8. Yuhas JM, Culo F: Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum (II) by WR-2721 without altering its antitumor properties. Cancer Treat Rep 64:57-64, 1980
9. Treskes M, Boven E, Loosdrecht AA, et al: Effects of the modulating agent WR-2721 on myelotoxicity and antitumour activity in carboplatin-treated mice. Eur J Cancer 30:183-187, 1994
10. Treskes M, Boven E, Holwerda U, et al: Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse. Cancer Res 52:2257-2260, 1992
11. Mollman JE: Protection against cis-platin neurotoxicity in cultured dorsal root ganglion cells by WR 2721. Seventh International Conference on Chemical Modifiers of Cancer Treatment. Clearwater, FL, February 2-5, 1991, pp 328-329
12. Müller LJ, Moorer-Van Delft CM, Treskes M, et al: WR-2721 protects neurons of the snail lymnaea stagnalis from cisplatin induced toxicity. Proc Am Assoc Cancer Res 33:557, 1992 (abstr 3330)
13. Grdina DJ, Sigdestad CP: Radiation protectors: The unexpected benefits. Drug Metab Rev 20:13-42, 1989
14. Nagy B, Dale PJ, Grdina DJ: Protection against cis-Diamminedichloroplatinum cytotoxicity and mutagenicity in V79 cells by 2-[(aminopropyl)amino]ethanethiol. Cancer Res 46:1132-1135, 1986
15. Nagy B, Grdina DJ: Protective effects of 2-[(aminopropyl)amino] ethanethiol against bleomycin and nitrogen mustard-induced mutagenicity in V79 cells. Int J Radiat Oncol Biol Phys 12:1475-1478, 1986
16. Grdina DJ, Nagy B, Sigdestad CP: Radioprotectors in treatment therapy to reduce risk in secondary tumor induction. Pharmacol Ther 39:21-25, 1988
17. Milas L, Hunter NR, Stephens LC, et al: Inhibition of radiation carcinogenesis in mice by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res 44:5567-5569, 1984
18. Glover DJ, Click JH, Weiler C, et al: Phase I/II trials of WR-2721 and cis-platinum. Int J Radiat Oncol Biol Phys 12:1509-1512, 1986
19. Glover DJ, Glick JH, Weiler C, et al: WR-2721 and high-dose cisplatin: An active combination in the treatment of metastatic melanoma. J Clin Oncol 5:574-578, 1987
20. Glover DJ, Glick JH, Weiler C, et al: WR-2721 protects against the hematologic toxicity of cyclophosphamide: A controlled phase II Trial. J Clin Oncol 4:584-588, 1986
21. Mollman JE, Glover DJ, Hogan WM, et al: Cisplatin neuropathy: Risk factors, prognosis and protection by WR-2721. Cancer 61:2192-2195, 1988
22. Ajani JA, Welch SR, Raber MN, et al: Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 8:147-159, 1990
23. Pocock SJ: Group sequential methods in the design and analysis of clinical trials. Biometrika 64:191-199, 1977
24. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
25. Gerhartz HH, Engelhard M, Meusers P, et al: Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood 82:2329-2339, 1993
26. Hoekman K, Wagstaff J, van Groeningen CJ, et al: Effects of recombinant human granulocyte-macrophage colony-stimulating factor on myelosuppression induced by multiple cycles of high-dose chemotherapy in patients with advanced breast cancer. J Natl Cancer Inst 83:1546-1553, 1991
27. Al-Sarraf M, Fletcher WS, Oishi N, et al: Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: A Southwest Oncology Group study. Cancer Treat Rep 66:31-35, 1982
28. Gonzalez-Vitale JC, Hayes DM, Cvitkovic E, et al: Acute renal failure after cis-dichlorodiammineplatinum(II) and gentamicin-cephalothin therapies. Cancer Treat Rep 62:693-698, 1978
29. DeSanto NG, Capasso G, Capodicasa G, et al: Acute renal failure due to cisplatin. Int J Pediatr Nephrol 7:145-150, 1986
30. Macleod PM, Tyrell CJ, Keeling DH: The effect of cisplatin on renal function in patients with testicular tumours. Clin Radiol 39:190-192, 1988
31. Madias NE, Harrington JT: Platinum nephrotoxicity. Am J Med 65:307-314, 1978
32. Dentino M, Luft FC, Yum MN, et al: Long-term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer 41:1274-1281, 1978
33. Fjeldborg P, Sorensen J, Helkjaer PE: The long-term effect of cisplatin on renal function. Cancer 58:2214-2217, 1986
34. Goren MP, Wright RK, Horowitz ME: Cumulative renal tubular damage associated with cisplatin nephrotoxicity. Cancer Chemother Pharmacol 18:69-73, 1986
35. Groth S, Nielson H, Srenson JB, et al: Acute and long-term nephrotoxicity of cis-platinum in man. Cancer Chemother Pharmacol 17:191-196, 1986
36. Aass N, Fossa SD, Aas M, et al: Renal function related to different treatment modalities for malignant germ cell tumors. Br J Cancer 62:842-846, 1990
37. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989
38. Egorin MJ, Van Echo DA, Olman EA, et al: Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedi-carboxylatoplatinum. Cancer Res 45:6502-6506, 1985
39. Sorensen BT, Stromgren A, Jakobsen P, et al: Dose-toxicity relationship of carboplatin in combination with cyclophosphamide in ovarian cancer patients. Cancer Chemother Pharmacol 28:397-401, 1991
40. Bleyer WA: The clinical pharmacology of methotrexate. Cancer 41:36-51, 1978
41. Haim N, Kedar A, Robinson E: Methotrexate-related deaths in patients previously treated with cis-diamminedichloride platinum. Cancer Chemother Pharmacol 13:223-225, 1984
42. Crom WR, Pratt CB, Green AA, et al: The effect of prior cisplatin therapy on the pharmacokinetics of high-dose methotrexate. J Clin Oncol 2:655-661, 1984
43. Goren MP, Wright RK, Horowitz ME, et al: Urinary N-acetyl-B-D-glucosaminidase and serum creatinine concentrations predict impaired excretion of methotrexate. J Clin Oncol 5:804-810, 1987
44. Yee GC, Crom WR, Champion JE, et al: Cisplatin-induced changes in bleomycin elimination. Cancer Treat Rep 67:587-589, 1983
45. Crooke ST, Comis RL, Einhorn LH, et al: Effects of variations in renal function on the clinical pharmacology of bleomycin administered as an IV bolus. Cancer Treat Rep 61:1631-1636, 1977
46. van Barneweld PWC, Sleiffer DT, van der Mark TW, et al: Influence of platinum-induced renal toxicity on bleomycin-induced pulmonary toxicity in patients with disseminated testicular carcinoma. Oncology 41:4-7, 1984
47. Blayney DW, Goldvert DA, Leong LA, et al: High-risk germ cell tumors in men. High response rate and severe toxicity with cisplatin, vinblastine, bleomycin, and etoposide. Cancer 71:2351-2357, 1993
48. Goren MP, Wright RK, Pratt CB, et al: Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy. Cancer Res 47:1457-1460, 1987
49. Pratt CB, Meyer WH, Jenkins JJ, et al: Ifosfamide, Fanconi's syndrome, and rickets. J Clin Oncol 9:1485-1499, 1991
50. Brade WP, Herdrich K, Varini M: Ifosfamide - Pharmacology, safety and therapeutic potential. Cancer Treat Rev 12:1-47, 1985
51. Wheeler BM, Loehrer PJ, Williams SD, et al: Ifosfamide in refractory male germ cell tumors. J Clin Oncol 4:28-34, 1986
52. Salem PA, Jabboury KW, Khalil MF: Severe nephrotoxicity: A probable complication of cis-dichlorodiammineplatinum(II) and cephalothin gentamicin therapy. Oncology 39:31-32, 1982
53. Walker EM, Fazekas-May MA, Bowen WR: Nephrotoxic and ototoxic agents. Clin Lab Med 10:323-354, 1990
54. Hansen SW, Groth S, Daugaard G, et al: Long-term effects on renal function and blood pressure of treatment with cisplatin, vinblastine, and bleomycin in patients with germ cell cancer. J Clin Oncol 6:1728-1731, 1988
55. Sterling Research Group: Plasma concentrations of radioactivity after a single intravenous dose of 14C-WR-2721 to male and female rats. Report No. 89/MS/05, Northumberland, United Kingdom, Alnwick, 1990
56. Swynnerton NF, Mangold DJ, Ludden TM: Measurement of ethiofos (WR-2721) in plasma: Preliminary pharmacokinetics in the beagle. J Liq Chromatogr 8:2675-2687, 1985
57. Swynnerton NF, Huelle BK, Mangold DJ: A method for the combined measurement of ethiofos and WR-1065 in plasma: Application to pharmacokinetic experiments with ethiofos and its metabolites. Int J Radiat Oncol Biol Phys 12:1495-1499, 1986
58. Shaw LM, Turrisi AT, Glover DJ, et al: Human pharmacokinetics of WR-2721. Int J Radiat Oncol Biol Phys 12:1501-1504, 1986
59. Shaw LM, Glover DJ, Turrisi A, et al: Pharmacokinetics of WR-2721. Pharmacol Ther 39:195-201, 1988
60. Shaw L, Bonner H, Nakashima H, et al: Pharmacokinetics of amifostine in cancer patients: Evidence for saturable metabolism. Proc Am Soc Clin Oncol 13:144, 1994 (abstr)
61. Calabro-Jones PM, Fahey RC, Smoluk GD, et al: Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721. Int J Radiat Biol 47:23-27, 1985
62. Smoluk GD, Fahey RC, Calabro-Jones PM, et al: Radioprotection of cells in culture by WR-2721 and derivatives: Form of the drug responsible for protection. Cancer Res 48:3641-3647, 1988
63. Calabro-Jones PM, Aguilera JA, Ward JF, et al: Uptake of WR-2721 derivatives by cells in culture: Identification of the transported form of the drug. Cancer Res 48:3634-3640, 1988
64. Yang JL, Fernandes DJ, Speicher L, et al: Biochemical determinants of the cytoprotective effect of amifostine. Proc Am Assoc Cancer Res 36:290, 1995 (abstr 1725)
65. Yuhas JM: Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res 40:1519-1524, 1980
66. Treskes M, Nijtmans LG, Fichtinger Schepman AMJ, et al: Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate. Biochem Pharmacol 43:1013-1019, 1992
67. Treskes M, Holwerda U, Nijtmans LGJ, et al: The reversal of cisplatin-protein interactions by the modulating agent WR2721 and its metabolites WR1065 and WR33278. Cancer Chemother Pharmacol 29:467-470, 1992
68. 60Co gamma-rays in mice. Int J Radiat Biol 61:387-392, 1992
69. Hunter NR, Guttenberger R, Milas L: Modification of radiation-induced carcinogenesis in mice by misonidazole and WR-2721. Int J Radiat Oncol Biol Phys 22:795-798, 1992
70. Ohnishi ST, Ohnishi T, Click JH, et al: In vitro study on the antioxidant activities of amifostine (WR-2721). Proc Am Assoc Cancer Res 33:419, 1992 (abstr 2503)
71. Dorr RT, Lagel KE: Anthracycline cardioprotection by amifostine (WR-2721) and its active metabolite (WR-1065) in vitro. Proc Am Soc Clin Oncol 13:435, 1994 (abstr 435)
72. Yuhas JM, Spellman JM, Jordan SW: Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide. Br J Cancer 42:574-585, 1980
73. Peters GJ, van der Wilt CL, Gyergyay F, et al: Protection by WR-2721 of the toxicity induced by the combination of cisplatin and 5-fluorouracil. Seventh International Conference on Chemical Modifiers of Cancer Treatment. Clearwater, FL, February 2-4, 1991, pp 333-334
74. US Bioscience: Effect of WR-2721 pretreatment on the cytotoxic activity of antineoplastic agents in human melanoma (SKMEL,28) and ovarian cancer (PA-1) cell lines.
75. US Bioscience: Effect of WR-2721 or WR-1065 pretreatment on the cytotoxic activity of antineoplastic agents on human ovarian cancer cells (BG-1).
76. US Bioscience: Effect of WR-1065 pretreatment on the cytotoxic activity of cisplatin on four human ovarian cancer cells lines.
77. Speicher LA, Krutzsh M, Wymer J, et al: Amifostine does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells. Proc Am Assoc Cancer Res 36:290, 1995 (abstr 1727)
78. Green D, Wright A, Schein PS, et al: WR-2721 chemoprotection of doxorubicin toxicity in mice. Proc Am Assoc Cancer Res 33:490, 1992
79. Alberts DS, Green S, Hannigan EV, et al: Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 10:706-717, 1992
80. Einhorn LH: Cis-diamminedichloroplatinum, vinblastine and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87:293-298, 1977
81. Kintzel PE, Dorr RT: Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev 21:33-64, 1995
82. Kaye SB, Lewis CR, Paul J, et al: Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 340:329-333, 1992
83. Hesketh PJ, Harvey WH, Harker WG, et al: A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol 12:596-600, 1994